Optimizing Activin Pathway Inhibition for Obesity – DIO Mouse Ffficacy as Monotherapy and in Combination with GLP-1 Agonism
Time: 3:40 pm
day: Day One
Details:
- Oral small molecule inhibitors of the Activin receptor type II (ACTRII) reduce fat mass and liver mass/fat while preserving muscle in DIO mice
- This activity is accompanied by an increase in energy expenditure, maintenance of fat loss even after discontinuation of GLP-1 agonist treatment, and correlates with downstream signaling pathway activity in various tissues
- In combination with GLP-1 agonist treatment, oral ACTRII inhibition significantly enhances fat loss while preserving liver and lean mass benefits
Speakers:
